Genetically-modified Autologous T Cells [EPC]

10160 reported adverse events

Drugs of this class: AXICABTAGENE CILOLEUCEL

These side effects are most commonly reported by patients taking drugs of the Genetically-modified Autologous T Cells [EPC] class:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 4622
1 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 2149
2 NEUROTOXICITY 1381
3 DEATH 1056
4 PYREXIA 906
5 DISEASE PROGRESSION 842
6 NEUTROPENIA 520
7 DIFFUSE LARGE B-CELL LYMPHOMA 403
8 HYPOTENSION 400
9 FEBRILE NEUTROPENIA 308
See all common reactions for Genetically-modified Autologous T Cells [EPC]

Drugs of the Genetically-modified Autologous T Cells [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CAR T-CELL-RELATED ENCEPHALOPATHY SYNDROME 115 0.9274
1 CYTOKINE INCREASED 76 0.5630
2 BCG RELATED CYSTITIS 9 0.4500
3 LYMPHOCYTE ADOPTIVE THERAPY 107 0.3835
4 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 2149 0.3625
5 MALIGNANT GENITOURINARY TRACT NEOPLASM 24 0.3582
6 IMMUNE EFFECTOR CELL-ASSOCIATED HAEMATOTOXICITY 58 0.3333
7 MYELODYSPLASTIC SYNDROME WITH MULTILINEAGE DYSPLASIA 14 0.2745
8 PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA 28 0.2393
9 CYTOKINE RELEASE SYNDROME 4622 0.2302
See all enriched reactions for Genetically-modified Autologous T Cells [EPC]